News

Further Year End Trading Update Milestone Payment for TMT®/TMTpro™ Sales
Further Year End Trading Update Milestone Payment for TMT®/TMTpro™ Sales
February 11, 2020

The Company is pleased to provide a further trading update for the financial year ended 31 December 2019.

 

Year End Trading Update
Year End Trading Update
January 21, 2020

The Company today provides a trading update for the financial year ended 31 December 2019.

Trading Update and Announcement of Board Changes
Trading Update and Announcement of Board Changes
October 31, 2019

Proteome Sciences plc (AIM: PRM) is pleased to announce that its services platform has continued to strengthen through the third quarter, during which a record number of 43 quotes for new business were issued.

Interim results for the six months ended 30 June 2019
Interim results for the six months ended 30 June 2019
July 25, 2019

Commenting on these results, Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said:

“Performance during the first six months of 2019 was very encouraging, building on the momentum developed in the second half of 2018.   Recognised revenues from our services platform were significantly ahead of the equivalent period in 2018 and, most importantly, we issued a record number of quotes for new business in the second quarter, a fundamental lead indicator of future customer engagement. 

Launch of new services powered by TMTpro 16plex
Launch of new services powered by TMTpro 16plex
July 1, 2019

Following the announcement of TMTpro 16plex isobaric mass tags during the American Society for Mass Spectrometry (ASMS) meeting in Atlanta in June, Proteome Sciences is launching upgrades to its core proteomic services (SysQuant®, TMTcalibrator™ and Plasma Super Depletion) with increased multiplexing.

 

New report on growing opportunities for TMT: “Tandem Mass Tag Usage Could Benefit From New Methods, Expanded Applications” available to premium subscribers of GenomeWeb
New report on growing opportunities for TMT: “Tandem Mass Tag Usage Could Benefit From New Methods, Expanded Applications” available to premium subscribers of GenomeWeb
June 24, 2019

New report on growing opportunities for TMT: “Tandem Mass Tag Usage Could Benefit From New Methods, Expanded Applications” available to premium subscribers of GenomeWeb.  Link here

Result of Annual General Meeting (AGM)
Result of Annual General Meeting (AGM)
April 30, 2019

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 2.30 p.m. today, all resolutions were duly passed.

A copy of the presentation given by the CEO, Jeremy Haigh, at the AGM will be available on the Company’s website tomorrow. Link here to AGM slides

 

Annual General Meeting (AGM) Statement and Q1 Trading Update
Annual General Meeting (AGM) Statement and Q1 Trading Update
April 30, 2019

At the Company’s AGM being held today at 2.30 pm the Chairman, Christopher Pearce, will make the following statement:

“As indicated in our recent results, we remain optimistic about the future, with the near-term availability of higher-plex TMT® set to add significant value to this asset, and the utility of quantitative proteomics increasing in response to diagnostic advances and disruptive technologies.  We are pleased to report a good first quarter, with further growth in sales and royalties from TMT® and an improving services business continuing the trend in orders and revenues established during the latter part of 2018.”  

Annual Report and Financial Statements 31 December 2018
Annual Report and Financial Statements 31 December 2018
April 3, 2019

The Annual Report and Accounts for the year ended 31 December 2018, together with a notice of the Annual General Meeting is available to view on the Companies website www.proteomics.com and will be posted to shareholders imminently.

Results for the year ended 31 December 2018 and Notice of AGM
Results for the year ended 31 December 2018 and Notice of AGM
April 2, 2019

The Company is pleased to announce its audited results for the year ended 31 December 2018.